Search
Search Results
##search.searchResults.foundPlural##
-
-
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4316PDF: 1763HTML: 1106 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4041PDF: 1151HTML: 1935Fig.1: 218Fig. 2: 111Table 1: 201Table2: 219Table 3: 199 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1070PDF: 388HTML: 89 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7434PDF: 2420HTML: 1732Table 1.: 208Table 2.: 217Table 3.: 201Table 4.: 200 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4753PDF: 2834HTML: 2281 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2082PDF: 1517HTML: 284 -
ADVANCES IN THE TREATMENT OF MALARIA
2842PDF: 1122HTML: 5991 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1417PDF: 901Suppl. Files: 454HTML: 235 -
-
BACTERIAL INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
3132PDF: 1823HTML: 3568 -
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA
1659PDF: 645HTML: 2431 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3935PDF: 1492HTML: 9188Untitled: 277Untitled: 183Untitled: 168Untitled: 164Untitled: 180Untitled: 338 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2760PDF: 1118HTML: 3283 -
LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
1275PDF: 891HTML: 1263fig 1A: 171figure1B: 145 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1240PDF: 985HTML: 211 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2221PDF: 1046HTML: 1982Characteristic of study group: 196 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
2933PDF: 981HTML: 2063Cover letter: 178 -
ASSESSMENT OF THE EFFICACY OF PROCALCITONIN, C-REACTIVE PROTEIN AND ALBUMIN LEVELS-GUIDED ANTIBIOTICS USE IN SEPSIS
931PDF: 496Html: 143Suppl. Files: 172 -
OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION
1101PDF: 542HTML: 1690Figures: 167Fifures Sanz: 176tables Sanz: 180Untitled: 176 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1721PDF: 1163HTML: 246 -
SOLITARY PLASMACYTOMA
3851PDF: 2175HTML: 1221fIGURES 1,2: 213 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3295PDF: 1342HTML: 2625 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2192PDF: 1487HTML: 266







